Deciphera’s Qinlock Hits GIST Roadblock With Phase III Failure

Cancer cells on scientific background.3d illustration
Deciphera reported that the Phase III trial of Qinlock in second-line GIST did not reach its primary endpoint • Source: Shutterstock

More from Anticancer

More from Therapeutic Category